Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Assets Average (2016 - 2025)

Fate Therapeutics' Assets Average history spans 13 years, with the latest figure at $331.3 million for Q4 2025.

  • For Q4 2025, Assets Average fell 29.18% year-over-year to $331.3 million; the TTM value through Dec 2025 reached $331.3 million, down 29.18%, while the annual FY2025 figure was $379.8 million, 19.78% down from the prior year.
  • Assets Average reached $331.3 million in Q4 2025 per FATE's latest filing, down from $357.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.0 billion in Q2 2021 to a low of $331.3 million in Q4 2025.
  • Average Assets Average over 5 years is $648.6 million, with a median of $585.9 million recorded in 2023.
  • Peak YoY movement for Assets Average: skyrocketed 167.3% in 2021, then plummeted 30.13% in 2025.
  • A 5-year view of Assets Average shows it stood at $953.0 million in 2021, then dropped by 23.67% to $727.5 million in 2022, then dropped by 27.83% to $525.0 million in 2023, then decreased by 10.89% to $467.8 million in 2024, then dropped by 29.18% to $331.3 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Assets Average are $331.3 million (Q4 2025), $357.7 million (Q3 2025), and $385.2 million (Q2 2025).